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Targeted therapies have made their way into clinical practice during the past decade. They have caused a major
impact on the survival of cancer patients in many areas of clinical oncology and hematology. Indeed, in some
hematologic malignancies, such as chronic myelogenous leukemia or non-Hodgkin’s lymphomas, biologicals and
antibodies specifically designed to target tumour-specific proteins have revolutionized treatment standards. In solid
tumours, new drugs targeting EGF- or VEGF- receptors are now approved and are entering clinical practise for
treatment of colon, lung, kidney and other cancers, either alone or in combination with conventional treatment
approaches.
Recent data have now shown that molecular targeted therapy might display efficacy in patients with head and
neck squamous cell carcinoma (HNSCC) as well. The evaluated biologicals are generally well tolerated from HNSCC
patients, who usually have the burden of multiple co-morbidities that interfere with conventional systemic treat-
ment options. Therefore, molecular targeted therapies offer new treatment options even for heavily pretreated and
seriously ill patients usually unable to tolerate chemotherapy or radiation therapy.
The two most promising and advanced strategies are the blockage of growth-factor based cellular signalling and
interference with angiogenesis-related pathways. But inhibitors of alternative targets, such as Scr and proteasomes,
have already been evaluated in early clinical trials with HNSCC patients.
Introduction
Squamous cell carcinoma of the head and neck
(SCCHN) represents the eighth leading cause of cancer
worldwide. Despite recent advances in surgery and
radiotherapy, overall cure is achieved in less than 50% of
patients. In contrast to many other cancers, distant
metastases are rarely present at diagnosis, but due to
better local control, the incidence of systemic spread is
rapidly increasing. Those with recurrent or metastatic
disease have a poor prognosis, with median survival
rates of 6-10 months [1]. Systemic chemotherapy
remains the only effective treatment option, but it is
associated with significant toxicity rates in HNSCC
patients, who usually have a high prevalence of co-mor-
bidities and problematic lifestyle habits [2]. Therefore,
additional treatment options that have the potential to
improve outcome and that show a toxicity profile differ-
ent from cytotoxic agents are desperately needed to
complement presently available treatment tools.
New agents that specifically target cellular pathways
associated with carcinogenesis are promising candidates,
because they are already successfully used in other
hematological malignancies as well as in solid tumours,
such as colorectal or lung cancer [3].
Two primary strategies that might have the potential
to change clinical routine within the near future will be
discussed in this review: first, blocking epidermal growth
factor-based cellular signalling (EGFR-associated) and
second, blocking angiogenesis related cellular signalling
(VEGFR-associated). In addition, we will review data on
new drugs that target molecular targets other than
EGFR and VEGF and discuss their relevance for
HNSCC treatment.
The role of EGF-R signalling in HNSCC
The EGF-R is a member of the human epidermal recep-
tor (HER)/Erb-B family, a group of tyrosine kinases that
transduce extracellular signals to intracellular responses
influencing cell proliferation, apoptosis, angiogenesis,
and the capacity of tumour cells to metastasize [4]. It
has been shown that EGF-R and TGF-a,o n eo ft h e
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many solid tumours, including colorectal cancer,
NSCLC, and HNSCC [5]. Furthermore, EGF-R-overex-
pression as well as increased m-RNA levels of TGF-a in
tumours are usually associated with poorer responses
to radiotherapy and have been shown to be strong pre-
dictors of decreased disease-free survival [6]. These
observations are the rationale for the development of
EGF-R-targeted therapies, which are intended to inter-
rupt EGF-R-mediated pathways.
Among EGF-R-targeting therapies, there are two large
categories of molecules: monoclonal antibodies, which
recognize the ligand-binding domain and interfere with
receptor activation, and tyrosine kinase inhibitors which
bind to the cytoplasmatic region and influence with
downstream signalling events.
Anti-EGF-R antibodies
Cetuximab is a chimeric human/murine monoclonal anti-
body of the IgG1 isotype that binds to the EGF-R with a
higher affinity than its endogenous ligands, preventing
dimerization, internalisation and autophosphorylation.
Preclinical studies show at least three different mechan-
isms by which cetuximab affects tumour cells. First, it
enhances tumour-cell apoptosis and inhibits proliferation
as well as invasiveness by blocking the tyrosine-kinase-
mediated pathways. Second, antibody-dependent cell-
mediated toxicity, which is associated specifically with the
IgG1 isotype, contributes to the anticancer activity. Finally,
cetuximab may block the nuclear import of EGF-R, pre-
venting activation of the DNA repair mechanism that pro-
tects cells from radiation- or chemotherapy-induced DNA
damage [7-9].
Two other anti-EGF-R MoABs are currently tested in
large clinical trials. Panitumumab is a fully human, IgG2
EGF-R-targeting antibody that is already approved for
metastatic colon cancer and is tested in locally advanced
disease in combination with radiotherapy[10]. Zalutu-
mumab, also a fully human antibody of the IgG1 type, is
currently being evaluated in a randomized phase III trial
concerning best supportive care for advanced platinum
refractory patients [11-14]. While the use of these both
agents remains experimental until study results are pub-
lished, profound clinical data are available for cetuxi-
mab, both in the adjuvant and palliative setting.
Cetuximab in locally advanced HNSCC
Cetuximab is approved in combination with irradiation
in locally advanced disease based on a multinational,
randomized phase III trial comparing radiotherapy plus
cetuximab with radiotherapy alone. Results published by
Bonner in 2006 demonstrated significantly prolonged
locoregional control and overall survival without
adversely affecting quality of life[15]. Risk of locoregio-
nal failure was significantly reduced, resulting in a
9-month increase in median locoregional control. Med-
ian overall survival could be prolonged to a median of
49 months (vs. 29 months). In addition, preservation of
larynx function, which is a major determinant of life
quality, seemed to be better in the cetuximab arm. As
expected from the experiences in other malignancies,
acneiforme rash and infusion-related reactions were the
only reported toxicities [16]. Although no data are avail-
able from studies comparing cetuximab plus
radiotherapy to the standard treatment of platin-based
radio-chemotherapy, this regimen has to be considered
an important alternative, particularly for patients in
poor medical condition.
Cetuximab in metastatic HNSCC
In previously untreated patients with metastatic
HNSCC, cisplatin-based chemotherapy is considered
standard. This approach is now challenged by the
recently published results of the EXTREME study (Erbi-
tux in First-line Treatment of Recurrent or Metastatic
Head and Neck Cancer). In this controlled randomized
phase III trial, 442 patients who were not amenable to
local therapy and had not received any systemic treat-
ment received either cisplatin or carboplatin, together
with 5-fluorouracil or a combination of this chemother-
apy with cetuximab. Preliminary data demonstrated
median survival times that differed significantly between
the two study arms. The addition of cetuximab pro-
longed OS from 7.4 months to 10.1 months and dis-
ease-free survival from 3.3 to 5.6 months [17]. Although
these data support the use of cetuximab in first-line
combinations, still many patients receive platin-contain-
ing chemotherapy combinations without cetuximab up
front. In case of recurrence, cetuximab monotherapy
might then offer a second-line option with significant
antitumour activity to these platin-resistant patients. In
a retrospective analysis Vermorken et al. found an abso-
lute increase of 2.5 months in median overall survival in
cetuximab-treated patients compared to historical con-
trols treated with best supportive care only[18]. In gen-
eral, response rates to cetuximab in studies examining
this pretreated patient population usually are in the
range of 6-20%. Interestingly, no further benefit could
be achieved adding cisplatin to cetuximab [19].
EGF-R-targeted tyrosine-kinase inhibitors
TKIs bind intracellularly to EGF-R tyrosine-kinase and
block downstream signalling pathways. Gefitinib and
erlotinib, both administered orally once a day, are the
two most advanced TKIs and are both approved for cer-
tain indications in non-small cell lung cancer. They
have been evaluated in phase I/II trials as monothera-
pies in recurrent or metastatic HNSCC with response
rates of 4-10%. Unfortunately, the only available phase
III study involving 486 patients with recurrent HNSCC
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length of survival with the addition of gefitinib at differ-
ent dosing schedules to methotrexate when compared
to methotrexate treatment alone [20].
Other studies are now evaluating gefitinib and erloti-
nib in combination with more aggressive chemotherapy
regimens, such as platinum or docetaxel, and either with
or without concurrent radiotherapy. Until these data are
available, the use of gefitinib and erlotinib remains
experimental, and important questions have to be
answered before clinical use can be recommended.
EGF-R and HER-2 combined targeted tyrosine-kinase
inhibitors
HER-2 has also been found to be expressed in a signifi-
cant proportion of EGF-R-positive HNSCCs. Since EGF-
R and HER-2 heterodimerize to form functional signal-
ling complexes, tyrosine-kinase inhibitors with dual spe-
cificity against HER-2 and EGF-R, such as lapatinib,
have been investigated in phase I and II studies. In one
of these studies lapatinib, which is already approved for
breast cancer treatment, showed disease stabilization
rates of about 20% in patients pretreated with anti-
EGFR compounds[21], and therefore its efficacy in the
adjuvant setting is currently being explored in ongoing
phase III studies. Furthermore the irreversible EGFR/
her-2 inhibitor BIBW-2992 is being compared head to
head with cetuximab in a randomized crossover study.
Due to its irreversible inhibition BIBW-2992 remains
active in many EGF-R mutations, including the EGF-
RvIII mutation, which has been reported in HNSCC.
The study completed enrollment in 2009 and initial
results are anticipated for 2010.
The role of angiogenesis in HNSCC
Similar to other solid tumours, angiogenesis plays an
important role in the pathogenesis of HNSCC. Vascu-
lar endothelial growth factors (VEGF) and its receptors
are expressed in most cases of HNSCC, and multiple
preclinical studies have shown that these markers are
associated with tumour progression, changes in micro-
vessel density, and development of lymph node metas-
tasis. In addition, increased levels of VEGF in serum of
patients with HNSCC appear to induce tumour
growth, metastasis, and treatment failure [22]. Nude
mice experiments have shown that inhibition of VEGF
pathways markedly decreases angiogenesis and tumour
growth [23]. Therefore several strategies to target
VEGF-mediated angiogenesis have been developed and
are currently being explored in clinical trials.
VEGF ligand targeted therapy
Bevacicumab is a fully humanized monoclonal antibody
binding VEGF with proven activity in colorectal, breast,
and non-small cell lung cancer. In HNSCC, bevacicu-
mab shows little single agent activity, but a small phase
I/II study in combination with erlotinib in metastatic or
incurable recurrent disease showed an overall response
rate of about 15% and a median survival of 7.1 months.
In general the regimen was well tolerated, with rash,
diarrhea, and fatigue as the predominant side effects.
But as in other entities, a small but significantly
increased risk of bevacicumab-associated bleeding events
have been reported in addition to other, more easily
manageable side effects, such as hypertension and fluid
retention, in this trial [24]. In several ongoing trials bev-
acicumab is currently being explored in combination
with chemotherapy, radiation therapy, or EGFR inhibi-
tors, but so far no clinical data are available to recom-
mend the use of bevacicumab in the clinical routine.
Small molecules targeting VEGF-receptor
Sorafenib and sunitinib are multikinase inhibitors that
are already approved for several other cancer types and
have shown their ability to inhibit the intracellular activ-
ity of VEGF-R and to block downstream signalling. Pro-
mising early clinical results were obtained in a small
trial in refractory or metastasizing HNSCC patients,
with single agent sorafenib achieving stable disease in
10/26 patients and a median overall survival of 8
months [25]. A non-randomized phase II trial evaluating
a combination of paclitaxel, carboplatin, and sorafenib is
currently ongoing. Sunitinib, which is approved for gas-
trointestinal stromal tumour and renal cell carcinoma,
as well as vandetanib, a selective dual inhibitor of EGFR
and VEGF pathways, are currently being evaluated in
phase II trials, either alone or in combination with cyto-
toxic chemotherapy in advanced HNSCC.
Other potential targets
Src kinases are involved in the regulation of a variety of
normal cellular signal transduction pathways, and they
influence cell proliferation, survival, angiogenesis, migra-
tion, and adhesion. In general, levels of Src expression
or activation in epithelial tumours correlate with disease
progression. It is important that Src activation results in
potentiation of EGF-R-mediated tumour growth by sti-
mulating the same downstream pathways like FAK,
STAT, and PI3K[26]. In fact, recently published in vitro
experiments show that Src family kinases are highly
activated in cetuximab-resistant cells and that they
enhance EGF-R activation despite the cetuximab-bound
receptor. In these experiments inhibition of Src kinases
in originally cetuximab-resistant cell lines resulted in a
regaining of sensitivity against cetuximab, indicating a
close interaction between Src and EGF-R regarding the
processes causing cetuximab resistance in tumour cells
[27].
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EGF-R and Src might, therefore, be a feasible strategy
f o ro v e r c o m i n go rp r e v e n t i n g acquired resistance to
cetuximab.
Dasatinib is a potent inhibitor of multiple oncogenic
kinases including Src, cKIT, BCR-ABL, PDGFR, and
ephrin A. Because of its ability to inhibit BCR-ABL, it
was approved for treatment of chronic myeloid leukemia
in 2006. Currently dasatinib is being evaluated in phase
I clinical trials for solid tumours either alone or in com-
bination with cetuximab [28].
Proteasomes are proteinases, which play a critical role
in degradation of the proteins responsible for the con-
trol of cell growth. Inhibitors of proteasomes have
demonstrated antitumour effects associated with the
induction of apoptosis and sensitization of malignant
cells to conventional cytotoxic drugs. Bortezomib, a
small molecule inhibitor of proteasomes, has shown effi-
cacy against myeloma and lymphomas, and was recently
tested in phase II trials in HNSCC in combination with
docetaxel or irinotecan, respectively[29]. Preliminary
results have shown 50% disease control rates in recur-
rent or metastasizing HNSCC patients with the use of
low-dose bortezomib[30]. Phase III trials with optimized
dosing schedules are needed to confirm these promising
new treatment options, which were usually associated
with acceptable toxicity.
Conclusion
Molecular targeted therapies are promising novel treat-
ment options for patients with HNSCC. While EGFR-
targeting approaches have shown significant but limited
efficacy and are already approved for treatment in
advanced HNSCC, other options, such as inhibitors of
antiangiogenesis, proteasomes, or multifunctional tyro-
sine kinases are currently evaluated in phase I or II stu-
dies, either as single agent treatment or in combination
with conventional cytotoxic drugs. Though multiple
questions regarding dosing, combination and patient
selection need to be answered, molecular targeted treat-
ment will complement conventional chemo- and radia-
tion therapy in patients with HNSCC in the near future.
Especially the low toxicity profiles of these new agents
are very promising. So far however, all molecular tar-
geted therapies with the exception of cetuximab should
be used in the context of clinical trials only.
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